University Of Rochester Scientists Test New Method To Attack Cancer

The research, led by Peter T. Rowley, M.D., of the University of Rochester Medical Center, is being presented today at the annual meeting of the American Association for Cancer Research in Washington, D.C.

The enzyme telomerase produces telomeres, located at the ends of each chromosome, which protect the ends of chromosomes as cells divide. In a normal cell, the telomeres shorten each time the cell divides. After a cell divides 50 to 100 times, the telomeres shorten so much that they can no longer protect the chromosome, and the cell eventually dies.

Scientists believe that such cell death is normal, even healthy. But as a healthy cell turns cancerous, a genetic mutation triggers the production of telomerase, which restores the telomeres to normal length. The restored telomeres enable the cell to divide, unchecked, thousands of times instead of the usual 50 to 100. Over time, a few cancer cells can multiply into a golf-ball-sized tumor or spread to other parts of the body.

Since researchers discovered the important role telomerase plays in most cancers in the mid-1990s, much attention has been focused on finding a way to attack them. Several methods are in various stages of development.

The University of Rochester team used RNA interference to disrupt the production of telomerase in various cancer cells including colon, skin, cervical, and lung cancer. They crafted tiny snippets of double-stranded RNA, tailored to seek out the chemical message in the cell that conveys the instructions for making telomerase. Those snippets attracted enzymes and, together, they sought out and destroyed the cells' chemical messages for making telomerase.

The technique reduced – but didn't fully block – the production of telomerase. But with the cells' supply of telomerase decreased, the telomeres at the ends of the chromosomes began to shorten. Over 75 days, the telomeres were shortened by as much as 85 percent. Rowley believes that if the experiment had been continued, the telomeres would have been shortened so much that all the cancer cells in the experiment would have died.

"If we can develop a therapy that prevents cancer cells from making telomerase, we may have a therapy that is effective against most cancers," said Rowley. "There are several hurdles we have to overcome before we can bring such a therapy to patients. Nonetheless, telomerase appears to be the most promising target we have in the search for an agent that is broadly effective against most forms of cancer."

Among the hurdles Rowley and other researchers are addressing is the possibility that RNA injected into the body could be broken down by enzymes before it reaches a patient's cancer cells. Rowley plans a new series of experiments in mice to explore that possibility and devise a strategy to overcome it.

The research was funded by grants from the National Institutes of Health, the National Leukemia Research Association, and the Elsa U. Pardee Foundation.